Crinetics Pharmaceuticals CRNX Business Segments — Selling, General and Administrative Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — selling, general and administrative expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — selling, general and administrative expense?
- Crinetics Pharmaceuticals (CRNX) reported business segments — selling, general and administrative expense of $50.83M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — selling, general and administrative expense changed year-over-year?
- Crinetics Pharmaceuticals's business segments — selling, general and administrative expense increased by 43.1% year-over-year, from $35.53M to $50.83M.
- What does business segments — selling, general and administrative expense mean?
- Captures the aggregate costs associated with operating the business, including administrative overhead, legal, marketing, and commercial support functions. This metric reflects the company's overall operational scale and the resources allocated to support corporate infrastructure and product commercialization. Monitoring this helps evaluate the company's ability to manage fixed costs while scaling operations.